Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study

presenting with NSTE-ACS. The patients will be loaded with standard dual antiplatelet therapy according to local practice (usually aspirin 81 to 330 mg and clopidogrel 300 mg or prasugrel 20 mg or ticagrelor

  • 0 views
  • 17 Nov, 2021
  • 13 locations
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.

endovascular intervention
peripheral vascular disease
ticagrelor
vascular disease
clopidogrel
  • 1 views
  • 14 Jun, 2022
  • 1 location
Mono Antiplatelet and Colchicine Therapy

The purpose of this study is to evaluate the efficacy and safety of aspirin-free, P2Y12 inhibitor single antiplatelet and colchicine treatment in patients with acute coronary syndrome treated with drug-eluting stents.

aspirin
stemi
  • 0 views
  • 09 Jul, 2021
  • 1 location
Mobilization of Endothelial Progenitor Cells and Aspirin (TROPHIC 3)

Aspirin at doses used during acute myocardial infarction may inhibit the mobilization of endothelial progenitor cells (EPCs).

  • 19 views
  • 12 May, 2022
  • 1 location
Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease

EFFECTIVENESS OF COMBINED ANTICOAGULATION AND ANTITHROMBOTIC THERAPY VS ANTITHROMBOTIC THERAPY ALONE AFTER LOWER EXTREMITY REVASCULARIZATION FOR PERIPHERAL ARTERIAL DISEASE.

Accepts healthy volunteers
  • 0 views
  • 15 May, 2022
  • 1 location
Brilinta Clinical Experience Investigation (BRLCEIACS/OMI)

, treatment for the event, and risk factors for these events, etc. Profile and incidence of ADRs not expected from "Precautions for Use" of the ticagrelor JPI Efficacy

  • 248 views
  • 02 Jul, 2022
  • 16 locations
Patients on Antithrombotics for Colonoscopy

The use of antithrombotics (antiplatelet agents and anticoagulants) is increasing with an aging global population.Management of antithrombotics in patients undergoing invasive procedures including gastrointestinal endoscopy remains a challenge. Management approach includes taking a precarious balance between the risk of thromboembolism after interruption of antithrombotics and risk of bleeding with the …

  • 1 views
  • 23 Mar, 2022
  • 1 location
Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI) (TRIDUAL-PCI)

Aim of this study is to describe clinical and procedural characteristics of real-world population initiated on triple antithrombotic therapy (double antiplatelet therapy+anticoagulant) or double antithrombotic therapy (single antiplatelet therapy+anticoagulant) after percutaneous coronary intervention (PCI). Investigator's driven trial, retrospective (2015-2019), multicenter Italian registry. Baseline clinical characteristics as well as procedural details …

rivaroxaban
pradaxa
thrombosis
thrombolytic
ticagrelor
  • 1 views
  • 28 Feb, 2022
  • 1 location
Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome (EvoACS)

The aim of the present study is to investigate the effects of evolocumab in addition to statin therapy on platelet reactivity in patients with acute coronary syndrome (ACS) while on Ticagrelor

  • 0 views
  • 27 Jun, 2022
  • 1 location
Effects of P2Y12 Receptor Inhibitors on Central and Peripheral Chemoreceptors' Sensitivity

Research project objectives: Most common complication of P2Y12 inhibitors treatment, particularly with ticagrelor, is dyspnea reported in 0 to 9.3% and in 10 to 38.6% of patients taking

  • 0 views
  • 20 Oct, 2021
  • 1 location